Lin T, Wang X, Gao H, et al. - Researchers performed this study among hemodialysis (HD) patients in order to assess the pharmacokinetic characteristics as well as the effectiveness of daclatasvir/sofosbuvir (DAC/SOF) and ledipasvir/SOF (LDV/SOF) in this patient population. They treated 7 patients with SOF coadministered with DAC or LDV once daily for 12 weeks. Six (100%) patients successfully achieved a sustained virologic response in week 12 (SVR12), except for the death of 1 patient because of severe cerebral hemorrhage not associated with antiviral therapy. The extraction ratio of SOF007 was estimated to be 66.67%, and the HD clearance of SOF007 was identified to be 5.65 L/h. Findings revealed not only the good tolerability but also the effectiveness of the combination of SOF with either DAC or LDV to afford high SVR12 in HD patients.